LY2523355

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2016
01220112016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
This first-in-human report examined the recommended Phase 2 dose and schedule of litronesib, a selective allosteric kinesin Eg5… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2015
2015
Intervention of cancer cell mitosis by antitubulin drugs is among the most effective cancer chemotherapies. However, antitubulin… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Eg5, a mitotic motor kinesin protein, plays an essential role in bipolar spindle formation in the M phase of the cell cycle… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2014
2014
Mitosis inhibitor (R)-litronesib (LY2523355) is a 1,3,4-thiadiazoline-bearing phenyl and N-(2-ethylamino)ethanesulfonamido-methyl… (More)
  • table 2
  • figure 1
  • table 1
  • table 3
  • figure 2
Is this relevant?
2011
2011
2600 Background: LY2523355 is an allosteric inhibitor of Eg5 which selectively inhibits bipolar mitotic spindle formation. The… (More)
Is this relevant?